Skip to main content
Novo NordiskIn development

Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and...

Source: Autobound Signal API · 94 signals tracked for Novo Nordisk · updated

Get Novo Nordisk's live signals in Claude or ChatGPT, or by API

AskWhat changed at Novo Nordisk this week? Use Autobound signals for novonordisk.com.

What happened

Novo Nordisk announced phase 3 REDEFINE 9 trial results for its investigational drug CagriSema showing ~21% average weight loss with lower doses.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

PLAINSBORO, N.J. and BAGSVÃRD, Denmark, Nov. 14, 2026 /PRNewswire/ -- Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg. 1 The results were presented at ObesityWeek ® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology. 1,2 "Understanding how people respond to treatment across different doses is an important part of obesity research," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek ® ." In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68...

Keep reading with a free account

The rest of this article, and every signal for Novo Nordisk, is in your free account.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Stories
2
Product
CagriSema
Takes effect
Nov 14, 2026
Location
Plainsboro, New Jersey, United States

The full record

From the Signal API record

Numbers

Stories about this event
2

Topics and mentions

Product tags

  • medical

Extraction

Confidence
95%
Detected
Nov 14, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Novo Nordisk and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Novo Nordisk this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/0ac18b8b-e5ea-2538-7690-982833a3ecd8 returns this record as JSON. POST /v1/companies/enrich returns every signal for novonordisk.com.

{
  "signal_id": "0ac18b8b-e5ea-2538-7690-982833a3ecd8",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-14T17:00:00+00:00",
  "company": {
    "name": "Novo Nordisk",
    "domain": "novonordisk.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/novos-investigational-cagrisema-a-glp-1-and-amylin-analog-demonstrated-21-average-weight-loss-with-lower-doses-in-the-redefine-9-trial-presented-at-obesityweek-2026-and-published-in-the-lancet-diabetes--endocrinology-302939556.html",
    "title": "Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes & Endocrinology",
    "excerpt": "PLAINSBORO, N.J. and BAGSVÃRD, Denmark , Nov. 14, 2026 /PRNewswire/ -- Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg. 1 The results were presented at ObesityWeek ® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology . 1,2 \"Understanding how people respond to treatment across different doses is an important part of obesity research,\" said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. \"REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek ® .\" In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68...",
    "product": "CagriSema",
    "summary": "Novo Nordisk announced phase 3 REDEFINE 9 trial results for its investigational drug CagriSema showing ~21% average weight loss with lower doses.",
    "location": "Plainsboro, New Jersey, United States",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS428726/NY80976LOGO.jpg?id=OA3077747&p=facebook",
    "confidence": 0.95,
    "product_data": {
      "name": "CagriSema",
      "full_text": "investigational CagriSema",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-14T17:00:00Z",
    "location_data": [
      {
        "city": "Plainsboro",
        "state": "New Jersey",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-11-14",
    "article_sentence": "Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.